Skip to main content

Table 2 Anticoagulation characteristics

From: Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists

  Total (n = 346) DOAC (n = 74) Vitamin K antagonist (n = 272) p
Anticoagulation indication
 Not specified 27 (7.8) 10 (13.5) 17 (6.2)  
 Atrial fibrillation 223 (64.5) 48 (64.9) 175 (64.3)  
 Thromboembolic event 74 (21.4) 13 (17.6) 61 (22.4)  
 Mechanical heart-valve 17 (4.9) 1 (1.4) 16 (5.9)  
 Coagulopathy 5 (1.4) 2 (2.7) 3 (1.1) 0.090
Additional platelet aggregation inhibitor therapy
 None 285 (82.4) 62 (83.8) 223 (82.0)  
 Acetylsalicylic acid 44 (12.7) 9 (12.2) 35 (12.9)  
 Clopidogrel 13 (3.8) 1 (1.4) 12 (4.4)  
 Acetylsalicylic acid + Clopidogrel 4 (1.2) 2 (2.7) 2 (0.7) 0.328
 Additional heparin 7 (2.0) 1 (1.4) 6 (2.2) 0.643
  1. Abbreviation: DOAC direct oral anticoagulants